Maze Therapeutics (NASDAQ:MAZE) Trading Up 8.4% – Time to Buy?

Maze Therapeutics, Inc. (NASDAQ:MAZE) was up 8.4% on Wednesday . The company traded as high as $36.50 and last traded at $36.02. Approximately 328,145 shares traded hands during mid-day trading, an increase of 6% from the average daily volume of 308,758 shares. The stock had previously closed at $33.23.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on MAZE shares. Raymond James Financial initiated coverage on shares of Maze Therapeutics in a research report on Thursday, November 13th. They set an “outperform” rating and a $48.00 target price on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Maze Therapeutics from $27.00 to $37.00 and gave the stock an “overweight” rating in a research report on Monday, September 29th. Guggenheim upped their price objective on Maze Therapeutics from $19.00 to $34.00 and gave the stock a “buy” rating in a report on Monday, September 15th. BTIG Research increased their price objective on Maze Therapeutics from $30.00 to $37.00 and gave the company a “buy” rating in a research report on Friday, September 12th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Maze Therapeutics in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $38.57.

Maze Therapeutics Stock Up 1.9%

The business has a fifty day moving average of $28.84 and a 200 day moving average of $18.70. The firm has a market cap of $1.74 billion and a P/E ratio of -1.73.

Maze Therapeutics (NASDAQ:MAZE) last posted its earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.08.

Insider Transactions at Maze Therapeutics

In related news, Director Richard H. Scheller sold 20,744 shares of the business’s stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $22.37, for a total transaction of $464,043.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Hedge Funds Weigh In On Maze Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Woodline Partners LP increased its position in shares of Maze Therapeutics by 10.0% in the 3rd quarter. Woodline Partners LP now owns 1,035,229 shares of the company’s stock valued at $26,843,000 after buying an additional 94,529 shares in the last quarter. XTX Topco Ltd bought a new position in Maze Therapeutics during the third quarter worth about $697,000. Susquehanna International Group LLP grew its stake in Maze Therapeutics by 53.0% in the third quarter. Susquehanna International Group LLP now owns 16,165 shares of the company’s stock valued at $419,000 after acquiring an additional 5,598 shares during the period. Parkman Healthcare Partners LLC acquired a new position in Maze Therapeutics in the third quarter valued at about $5,186,000. Finally, Nantahala Capital Management LLC bought a new stake in shares of Maze Therapeutics in the third quarter worth about $2,421,000.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.